Skip to main content
Journal cover image

Myelotoxicity from chemotherapy.

Publication ,  Journal Article
Daniel, D; Crawford, J
Published in: Semin Oncol
February 2006

Myelosuppression continues to be a major dose-limiting toxicity for most chemotherapy regimens. While the development of growth factors has changed the approach to myelosuppression, costs remain high and can be measured both in terms of quality of life (QOL) and economic outcomes. Growing data suggest that there may also be effects on response and survival in some tumors. This review will highlight the incidence, effect, and treatment/prevention of myelosuppression and briefly discuss the questions that remain.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Semin Oncol

DOI

ISSN

0093-7754

Publication Date

February 2006

Volume

33

Issue

1

Start / End Page

74 / 85

Location

United States

Related Subject Headings

  • Thrombocytopenia
  • Risk Factors
  • Quality of Life
  • Oncology & Carcinogenesis
  • Neutropenia
  • Neoplasms
  • Middle Aged
  • Humans
  • Clinical Trials as Topic
  • Bone Marrow
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Daniel, D., & Crawford, J. (2006). Myelotoxicity from chemotherapy. Semin Oncol, 33(1), 74–85. https://doi.org/10.1053/j.seminoncol.2005.11.003
Daniel, Davey, and Jeffrey Crawford. “Myelotoxicity from chemotherapy.Semin Oncol 33, no. 1 (February 2006): 74–85. https://doi.org/10.1053/j.seminoncol.2005.11.003.
Daniel D, Crawford J. Myelotoxicity from chemotherapy. Semin Oncol. 2006 Feb;33(1):74–85.
Daniel, Davey, and Jeffrey Crawford. “Myelotoxicity from chemotherapy.Semin Oncol, vol. 33, no. 1, Feb. 2006, pp. 74–85. Pubmed, doi:10.1053/j.seminoncol.2005.11.003.
Daniel D, Crawford J. Myelotoxicity from chemotherapy. Semin Oncol. 2006 Feb;33(1):74–85.
Journal cover image

Published In

Semin Oncol

DOI

ISSN

0093-7754

Publication Date

February 2006

Volume

33

Issue

1

Start / End Page

74 / 85

Location

United States

Related Subject Headings

  • Thrombocytopenia
  • Risk Factors
  • Quality of Life
  • Oncology & Carcinogenesis
  • Neutropenia
  • Neoplasms
  • Middle Aged
  • Humans
  • Clinical Trials as Topic
  • Bone Marrow